Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001628280-21-021485
Filing Date
2021-11-03
Accepted
2021-11-03 16:26:33
Documents
49
Period of Report
2021-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q cort-20210930.htm   iXBRL 10-Q 1090451
2 EX-31.1 cort93021ex311.htm EX-31.1 9537
3 EX-31.2 cort93021ex312.htm EX-31.2 9623
4 EX-32.1 cort93021ex321.htm EX-32.1 5198
5 EX-32.2 cort93021ex322.htm EX-32.2 5124
  Complete submission text file 0001628280-21-021485.txt   4122929

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cort-20210930.xsd EX-101.SCH 25918
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT cort-20210930_cal.xml EX-101.CAL 58324
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT cort-20210930_def.xml EX-101.DEF 70977
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT cort-20210930_lab.xml EX-101.LAB 326075
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT cort-20210930_pre.xml EX-101.PRE 191466
11 EXTRACTED XBRL INSTANCE DOCUMENT cort-20210930_htm.xml XML 649612
Mailing Address 149 COMMONWEALTH DRIVE MENLO PARK CA 94025
Business Address 149 COMMONWEALTH DRIVE MENLO PARK CA 94025 650.688.8803
CORCEPT THERAPEUTICS INC (Filer) CIK: 0001088856 (see all company filings)

EIN.: 770487658 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-50679 | Film No.: 211375817
SIC: 2834 Pharmaceutical Preparations